In our study, the analysis of cytopathological sections from patients with cancer revealed higher CD32b expression levels in the advanced tumor stages (T2–T4, n = 26) compared to those of the earlier stages (T0–T1, n = 6), suggesting a potential role for CD32b in tumor progression (Figure 5, Table 2). The gene discussed is FCGR2B; the disease is cancer.